Carbamazepine

Carbamazepine has been studied in 12 papers since 2020: 9 observational studies in people, 1 in animals, 2 reviews; 5 in the past year. It is an approved medicine.

Intervention Approved 1968

12 papers study it6 more mention it5 findingsUpdated Oct 3, 2026

PubChem ChEBI MeSH

See all 17 papers on carbamazepine

At a glance

The findings reach people, from one lab or study. 2 independent labs in 2 countries; 91 trials, none about aging, 59 with no results posted.

“lumbar spine T-score declined significantly (-1.88 to -2.05; Cohen's d=0.61; p=0.011)”

Impact of Anti-epileptic Drugs on Bone Health – A Prospective Observational StudyPAIN JOINTS SPINE2026doi:10.1922/pjs.16.6s.2026.849

None of its findings points the other way.

2 independent labs in 2 countries
91 trials, none about aging, 59 with no results posted

Funders: National Institutes of Health and 4 more
1 of 91 trials sponsored by its developers

Humans9
Model organisms1

What did studies of carbamazepine find?

Studies of carbamazepine measured 5 outcomes, among them bone mineral density, hyperexcitability of aging male diagonal muscles and daf-16.

Bone mineral density

downin humans1

1 study

Carbamazepine is linked with lower bone mineral density in humans (long-term antiepileptic drug therapy) (-1.88 to -2.05, Cohen's d=0.61, p=0.011).
“lumbar spine T-score declined significantly (-1.88 to -2.05; Cohen's d=0.61; p=0.011)”
Humanslong-term antiepileptic drug therapylumbar spinesix monthsn = 21
Impact of Anti-epileptic Drugs on Bone Health – A Prospective Observational Study
PAIN JOINTS SPINEJul 6, 2026

Has carbamazepine been tested in people?

0 of 91 about aging

Yes: 9 observational studies in people have been published, and 91 trials are registered.

Approved

FDA Tegretol
Mar 11, 1968Epilepsy, Seizures, Trigeminal Neuralgia, Partial Seizures, generalized seizures, tonic-clonic seizures
FDA Tegretol
Dec 14, 1981Discontinued
FDA Tegretol
Dec 18, 1987Epilepsy, Seizures, Trigeminal Neuralgia, Partial Seizures, generalized seizures, tonic-clonic seizures
FDA Tegretol-XR
Mar 25, 1996Epilepsy, Seizures, Trigeminal Neuralgia, Partial Seizures, generalized seizures, tonic-clonic seizures
FDA Carbatrol
Sep 30, 1997Epilepsy, Seizures, Trigeminal Neuralgia, Partial Seizures, generalized seizures, tonic-clonic seizures
FDA Equetro
Dec 10, 2004Epilepsy, Seizures, Trigeminal Neuralgia, Bipolar I Disorder, Partial Seizures, generalized seizures, tonic-clonic seizures

All 7

Repurposing

Dementia
Phase 3Terminated1 trial
Depression
Phase 3Terminated1 trial
Asthma
Phase 4Completed2 trials
Schizophrenia
Phase 3Terminated2 trials
Anxiety disorders
Phase 3Terminated1 trial
Bipolar disorder
Phase 4Completed7 trials

All 33

In trials

Infantile spasms
Phase 2Completed1 trial
Clinical pharmacology
Phase 1Completed1 trial
Phenylketonurias
Phase 1Recruiting1 trial

Readouts due

Dec 14, 2026
A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Verducatib in the Blood
Phase 1Recruiting
May 2, 2027
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults
Phase 1Active, not recruiting

Stopped

NCT02623504TerminatedBipolar disorder
No apparent therapeutic effects that was superior to placebo
NCT06965881TerminatedFocal cortical dysplasia
Study was terminated due to the lack of operational capabilities of the sites to segregate participants as needed.

Who is developing carbamazepine?

3 companies: GRIN Therapeutics, DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Boehringer Ingelheim.

Companies: GRIN TherapeuticsPhase 1tuberous sclerosis complex, focal cortical dysplasia
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli LillyPhase 1
Boehringer IngelheimPhase 1